These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22204569)

  • 1. The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial.
    Chen L; Phillips G; Johnston J; Kinon BJ; Ascher-Svanum H; Kollack-Walker S; Succop P; Naber D
    BMC Psychiatry; 2011 Dec; 11():203. PubMed ID: 22204569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
    Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
    Lipkovich IA; Deberdt W; Csernansky JG; Sabbe B; Keefe RS; Kollack-Walker S
    BMC Psychiatry; 2009 Jul; 9():44. PubMed ID: 19602273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling.
    Llorca PM; Blanc O; Samalin L; Bosia M; Cavallaro R;
    Eur Psychiatry; 2012 Aug; 27(6):396-400. PubMed ID: 21723098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function.
    Kleinman L; Lieberman J; Dube S; Mohs R; Zhao Y; Kinon B; Carpenter W; Harvey PD; Green MF; Keefe RS; Frank L; Bowman L; Revicki DA
    Schizophr Res; 2009 Feb; 107(2-3):275-85. PubMed ID: 19013769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.
    Naber D; Kollack-Walker S; Chen J; Stauffer VL; Kinon BJ; Case M; Ascher-Svanum H; Kapur S; Kane JM
    Pharmacopsychiatry; 2013 May; 46(3):114-9. PubMed ID: 23293013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subjective well-being, but not subjective mental functioning shows positive associations with neuropsychological performance in schizophrenia-spectrum disorders.
    Schroeder K; Huber CG; Jelinek L; Moritz S
    Compr Psychiatry; 2013 Oct; 54(7):824-30. PubMed ID: 23602393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures.
    Fervaha G; Foussias G; Siddiqui I; Agid O; Remington G
    Schizophr Res; 2014 Apr; 154(1-3):89-92. PubMed ID: 24630140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment.
    Hunter R; Barry S
    Eur Psychiatry; 2012 Aug; 27(6):432-6. PubMed ID: 21602034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
    Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
    World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self- and caregiver-perceived disability, subjective well-being, quality of life and psychopathology improvement in long-acting antipsychotic treatments: a 2-year follow-up study.
    Pietrini F; Tatini L; Santarelli G; Brugnolo D; Squillace M; Bozza B; Ballerini A; Ricca V; D'Anna G
    Int J Psychiatry Clin Pract; 2021 Sep; 25(3):307-315. PubMed ID: 34057873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
    Perlick DA; Rosenheck RA; Kaczynski R; Bingham S; Collins J
    Schizophr Res; 2008 Feb; 99(1-3):192-9. PubMed ID: 17851042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
    Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
    Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.